NasdaqGM - Nasdaq Real Time Price ? USD Lantheus Holdings, Inc. (LNTH) Follow Compare 111.96 +1.24 (+1.12%) At close: October 15 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Is Lantheus Holdings (LNTH)The Most Undervalued Quality Stock To Buy According To Analysts? We recently compiled a list of the 10 Most Undervalued Quality Stocks To Buy According To Analysts. In this article, we will look at where Lantheus Holdings (NASDAQ:LNTH) ranks among the most undervalued quality stocks to buy according to analysts. Are More Rate Cuts Necessary to Maintain The Current Economic Trajectory? Despite global uncertainties, the […] Insider Monkey ? 3 days ago LNTH +1.12% Lantheus Holdings (NASDAQ:LNTH) Is Very Good At Capital Allocation If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for... Simply Wall St. ? 7 days ago LNTH +1.12% Medical Leader Lantheus Headed Toward Buy Point After Support At Key Level Lantheus stock is approaching a new buy point on the stock market today after finding support at a key level in recent weeks. Investor's Business Daily ? 20 days ago LNTH +1.12% Robust Quarterly Result Lifted Lantheus (LNTH) in Q2 ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here. Despite strong performance from healthcare holdings, the Strategy lagged its benchmark, the Russell 2000 Value Index, due to headwinds in the materials and industrial sectors. While investors continued […] Insider Monkey ? 21 days ago LNTH +1.12% Questor: A 300pc share price rise reflects the value of this cancer spotter “So, what seems to be the problem?” The Telegraph ? 23 days ago LNTH +1.12% Lantheus Holdings (NASDAQ:LNTH) shareholder returns have been fantastic, earning 306% in 3 years We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many... Simply Wall St. ? 28 days ago LNTH +1.12% Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was <1.00 when Assessed Using Two- GlobeNewswire ? 30 days ago LNTH +1.12% Lantheus Appoints Julie Eastland as New Board Member BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus’ Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a membe GlobeNewswire ? last month LNTH +1.12% DVAX We Ran A Stock Scan For Earnings Growth And Lantheus Holdings (NASDAQ:LNTH) Passed With Ease It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story... Simply Wall St. ? last month LNTH +1.12% Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4. To access a live webcast of the presentation, please visit the Investo GlobeNewswire ? last month LNTH +1.12% Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 BEDFORD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the Mayo Clinic in Rochester, Minnesota, will deliver an oral presentation, including additional clinical data from PNT2002’s init GlobeNewswire ? last month LNTH +1.12% Insider Sale: Director Gerard Ber Sells 15,500 Shares of Lantheus Holdings Inc (LNTH) Following this transaction, the insider now owns 21,221 shares of the company. Lantheus Holdings Inc is engaged in the development, manufacture, and commercialization of diagnostic and therapeutic products. Over the past year, the insider transaction history for Lantheus Holdings Inc shows a trend of more sales than purchases among insiders. GuruFocus.com ? 2 months ago LNTH +1.12% Lantheus Holdings' (NASDAQ:LNTH) Earnings Are Weaker Than They Seem Despite announcing strong earnings, Lantheus Holdings, Inc.'s ( NASDAQ:LNTH ) stock was sluggish. Our analysis... Simply Wall St. ? 2 months ago LNTH +1.12% Lantheus Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags Lantheus Holdings ( NASDAQ:LNTH ) Second Quarter 2024 Results Key Financial Results Revenue: US$394.1m (up 23% from 2Q... Simply Wall St. ? 2 months ago LNTH +1.12% Lantheus Holdings: Q2 Earnings Snapshot LNTH) on Wednesday reported second-quarter net income of $62.1 million. On a per-share basis, the Bedford, Massachusetts-based company said it had net income of 88 cents. Earnings, adjusted for one-time gains and costs, were $1.80 per share. Associated Press Finance ? 2 months ago LNTH +1.12% Lantheus Reports Second Quarter 2024 Financial Results Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023Completed three strategic transactions to expand innovative pipelineGAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.The Company maintains full year 2024 revenue guidance and updates fully GlobeNewswire ? 2 months ago LNTH +1.12% Nanotechnology in medicine: Who are the leading public companies? Applications for nanotechnology in medicine include imaging, diagnosis, or the delivery of drugs that will help medical professionals treat various diseases. Medical Device Network ? 2 months ago BHC MRK NVO Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second quarter of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen m GlobeNewswire ? 2 months ago LNTH +1.12% Lantheus Acquires NAV-4694, a Next-Generation ? Amyloid PET Imaging Agent for Alzheimer’s Disease Acquisition Expands Pipeline and Strengthens Alzheimer’s Diagnostic CapabilitiesBEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acquisition of Meilleur Technologies, Inc., which includes NAV-4694, expanding Lantheus’ Alzheimer’s disease pipeline. Through this acquisition, L GlobeNewswire ? 2 months ago LNTH +1.12% Lantheus Stock Gets A Radioactive Surge On Medicare Proposal Lantheus stock rocketed to a record high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics. Investor's Business Daily ? 3 months ago LNTH +1.12% Performance Overview Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return LNTH S&P 500 YTD +80.58% +21.92% 1-Year +65.94% +34.37% 3-Year +383.00% +31.03%
